Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Radiofrequency Ablation × 90 days × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT03753659 2026-03-23

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed
30 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡